Study Of Gene Expression Of Indomethacin On INOS And COX-2 In Human Laryngeal Cancer Cells Hep-2

The laryngeal cancer is a common squamous cell carcinoma of the head and neck,and the incidence rate of this cancer is the highest among squamous cell carcinomas of the head and neck. Although the clinical therapeutic methods are improving, therapeutic efficacy still unsatisfactory,especially in advanced stage laryngeal cancer. It is needed to develop a effective medicine for laryngeal cancer. In recent studies show indomethacin a kind of Non-steroid anti-inflammatory drug(NSAIDs)with dephlogistic and antipyretic analgesic speciality can decline in the risk with many common malignant tumors. And studies found that indomethacin can prevent and inhibit laryngeal cancer, but there are not reports about the clarity mechanism in that. In the present study, we investigated the mechanism of the inhibition of Hep-2 cells in human laryngeal cancer by indomethacin in three facts. Firstly, we investigated the oxidization damage by indomethacin though detecting the activity of superoxide dismutase and the content of malonaldehyde in Hep-2 cell fluid, using enzymic method and spectrophotometric method. And then we investigated the relation between gene inducible nitric oxide synthase (iNOS ) and the inhibition of Hep-2 cells in human laryngeal cancer by indomethacin, by enzymic method, spectrophotometric method, Western blot method and Semi-quantitative RT-PCR method. At last we investigated the relation between gene cyclooxygenase-2 (COX-2) and the inhibition of Hep-2 cells in human laryngeal cancer by indomethacin, by Western blot method and Semi-quantitative RT-PCR method. On the base of above investigation we explored the relations among the oxidization damage, gene iNOS, gene COX-2 and the inhibition of Hep-2 cells in human laryngeal cancer by indomethacin.